HIMS Q3 Earnings Are Out - Stock Plunges 10% on Misses Across the Board

Hims & Hers Health just reported Q3 2026 earnings, with shares initially down 10% following the report. Revenue, earnings, and guidance all fell short of Wall Street’s expectations.

• Revenue: $890.4 million vs. $893 million expected 🔴
• EPS: -$0.14 vs. $0.06 expected 🔴
• Adjusted EBITDA: $82.4 million vs. $85.1 million expected 🔴
• Gross Margin: 57%, down 17 percentage points year over year
• Free Cash Flow: $26 million

Guidance:

• Q4 Revenue: $875M–$895M vs. $953M expected 🔴
• Q4 Adjusted EBITDA: $70M–$90M vs. $107M expected 🔴
• FY26 Revenue: $3.13B–$3.15B vs. $3.21B expected 🔴
• FY26 Adjusted EBITDA: $257M–$277M vs. $295M expected 🔴

Quick Read:

Revenue soared 49% year over year, driven by strong international growth of 321%, but earnings missed expectations and gross margins contracted sharply.

Weak guidance is the biggest concern, with Q4 revenue projected well below Wall Street estimates and adjusted EBITDA also falling short, raising questions about profitability heading into 2027.